Profilnine

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1987-2017
0119872017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Recombinant factor VIIa (rFVIIa) is used in the management of bleeding in patients with hemophilia. A generic biosimilar version… (More)
Is this relevant?
Review
2016
Review
2016
BACKGROUND Reversal of warfarin-induced coagulopathy after traumatic injury may be done exclusively with prothrombin complex… (More)
  • table 1
  • table 2
  • figure 2
  • table 3
  • table 4
Is this relevant?
2014
2014
BACKGROUND Dabigatran is a potent oral anticoagulant. Like any anticoagulant, there is an increased risk of bleeding associated… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2013
2013
Currently, several newer oral anticoagulants namely dabigatran (anti-IIa), rivaroxaban (anti-Xa), and apixaban are available for… (More)
Is this relevant?
Review
2012
Review
2012
BACKGROUND AND PURPOSE The effectiveness of prothrombin complex concentrate (PCC) products available in the United States that… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
Is this relevant?
Review
2010
Review
2010
We report our initial experience using Profilnine SD, a 3-Factor prothrombin complex concentrate (PCC) in combination with fresh… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Plasma transfusion is standard therapy for urgent warfarin reversal in the United States. "Four-factor" prothrombin… (More)
Is this relevant?
2001
2001
Factor X (FX) deficiency is an autosomal recessive trait that occurs in fewer than 1 in 500 000 people. Not surprisingly, reports… (More)
Is this relevant?
1991
1991
We have studied the potential thrombogenicity of two different heat-treated prothrombin complex concentrates (PCC) in patients… (More)
Is this relevant?
1987
1987
Nineteen patients, (2 adults, 17 children) with inherited bleeding disorders were infused with n-heptane-suspended-heated… (More)
Is this relevant?